249 related articles for article (PubMed ID: 32852603)
1. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study.
Cao G; Hua D; Li J; Zhang X; Zhang Z; Zhang B; Bei T; Cui L; Chen S; Wang S; Zhu L
Front Immunol; 2023; 14():1022942. PubMed ID: 36993949
[TBL] [Abstract][Full Text] [Related]
4. Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
Khairallah AS; Genestie C; Auguste A; Leary A
Int J Cancer; 2018 Jul; 143(1):8-15. PubMed ID: 29218796
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Liang Y; Lü W; Zhang X; Lü B
Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).
Tavira B; Iscar T; Manso L; Santaballa A; Gil-Martin M; García García Y; Romeo M; Iglesias M; de Juan Ferré A; Barretina-Ginesta MP; Manzano A; Gaba L; Rubio MJ; de Andrea CE; González-Martín A
Clin Cancer Res; 2024 Jan; 30(1):176-186. PubMed ID: 37527007
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
Li J; Wang J; Chen R; Bai Y; Lu X
Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
[TBL] [Abstract][Full Text] [Related]
8. Platinum-based neoadjuvant chemotherapy upregulates STING/IFN pathway expression and promotes TILs infiltration in NSCLC.
Gao H; Zhang X; Ren M; Jiang A; Liu N; Wang J; Zheng X; Liang X; Ruan Z; Tian T; Fu X; Yao Y
Front Oncol; 2024; 14():1346225. PubMed ID: 38425343
[TBL] [Abstract][Full Text] [Related]
9. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of tumor infiltrating lymphocytes in high-grade serous ovarian carcinoma].
Huang XM; Zhang Y; Xu L; Wang M; Wang W
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):610-614. PubMed ID: 31422591
[No Abstract] [Full Text] [Related]
12. VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
Jlassi A; Manai M; Morjen M; Sahraoui G; Elasmi Allal M; ELBini-Dhouib I; Naija L; Charfi L; Rejaibi R; Ben Ahmed M; Marrakchi N; Srairi-Abid N; Mezlini A; Manai M; Mrad K; Doghri R
PLoS One; 2023; 18(3):e0278849. PubMed ID: 36952478
[TBL] [Abstract][Full Text] [Related]
13. Immunological impact of chemotherapy on the tumor microenvironment in gastric cancer.
Wei Q; Xu Q; Yuan X; Li JJ; Chen L; Luo C; Zhu X; Ying JE
J Surg Oncol; 2021 May; 123(8):1708-1715. PubMed ID: 33684248
[TBL] [Abstract][Full Text] [Related]
14. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
15. Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: Possible effects of in situ disorganized glucocorticoid production on tumor immunity.
Ishikawa Y; Yamazaki Y; Tezuka Y; Omata K; Ono Y; Tokodai K; Fujishima F; Kawanabe S; Katabami T; Ikeya A; Yamashita M; Oki Y; Nanjo H; Satoh F; Ito A; Unno M; Kamei T; Sasano H; Suzuki T
J Steroid Biochem Mol Biol; 2024 Apr; 238():106462. PubMed ID: 38232786
[TBL] [Abstract][Full Text] [Related]
16. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
17. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.
Pölcher M; Braun M; Friedrichs N; Rudlowski C; Bercht E; Fimmers R; Sauerwald A; Keyver-Paik MD; Kübler K; Büttner R; Kuhn WC; Hernando JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):909-19. PubMed ID: 20087581
[TBL] [Abstract][Full Text] [Related]
18. High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.
Ölmez F; Oğlak SC; Ölmez ÖF; Akbayır Ö; Yılmaz E; Akgöl S; Konal M; Seyhan NA; Kinter AK
Turk J Obstet Gynecol; 2022 Sep; 19(3):246-256. PubMed ID: 36149309
[TBL] [Abstract][Full Text] [Related]
19. Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer.
Feng X; Meng X; Tang D; Guo S; Liao Q; Chen J; Xie Q; Liu F; Fang Y; Sun C; Han Y; Ai J; Li K
Cancer Pathog Ther; 2024 Jan; 2(1):38-49. PubMed ID: 38328710
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
Bixel K; Vetter M; Davidson B; Berchuck A; Cohn D; Copeland L; Fowler JM; Havrilesky L; Lee PS; O'Malley DM; Salani R; Valea F; Alvarez Secord A; Backes F
Gynecol Oncol; 2020 Mar; 156(3):530-534. PubMed ID: 31937450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
